Following the news of the completion of the on-site inspection for a liver cancer treatment manufacturing facility, related biotech stocks showed strong gains. Some of the points raised during the inspection were categorized as issues that can be resolved through the company's voluntary corrective actions. The company is currently preparing materials for resubmission in cooperation with its partners. The market is focused on the possibility that this progress in procedures may lead to a resubmission. However, there are still stages that need to be confirmed, such as the actual application, review, and final approval. It is also important to note that the waiting period for business progress may differ from investors' financial schedules.


If you want to continue monitoring the follow-up review process, but repayment dates for margin or credit transactions approach first, it is necessary to review both your holding strategy and required funds. Investors using margin or credit trading, in particular, can mitigate the risks of forced liquidation by considering whether refinancing existing positions is possible. By checking usage conditions suitable for their accounts through financial consultations that consider interest rates and repayment obligations, investors can develop precise fund management plans—regardless of the new drug's progress.


HISTOCKLOAN has maintained its number one position in the industry for 22 years, offering a range of stock financing products, including products with annual interest rates in the 5% range. It can be used not only for securing new investment funds but also to refinance existing margin and credit trades at lower costs, making it a preferred choice for investors looking to maintain investment opportunities while improving capital efficiency.

If Repayment Dates Come Before New Drug Review... Consider Lower-Burden Margin and Credit Refinancing View original image

[Go to industry-leading HISTOCKLOAN: https://www.hisl.co.kr]


◆ HISTOCKLOAN: Industry's lowest annual interest rates in the 5% range—secure additional investment funds and refinance both margin and credit trades!

At "HISTOCKLOAN," anyone can experience stock loans with no burden, as a securities-linked credit product is now available at an industry-low interest rate in the annual 5% range. Not only can you use it for stock purchases, but both brokerage firm margin/credit refinances are also possible. Regardless of credit rating, you can leverage up to four times your own capital. Investors using the alternative trading platform (NXT) can also access this offering.


For investors seeking more information on HISTOCKLOAN’s diverse tailored products, simply contact the customer support center (☎1566-5113). Professional consultants are available 24 hours a day for convenient consultation, regardless of loan approval.


○ Launch of industry-low annual 5% range interest products

○ ETF trading available

○ 22 consecutive years at No. 1 in market share, 17 consecutive years awarded Korea First Brand Grand Prize

○ Real-time repayment for brokerage margin/credit trades

○ Alternative trading platform (NXT) available

○ Trusted quality assurance on consultation

* HISTOCKLOAN Consultation Center: 1566-5113

Go directly: https://www.hisl.co.kr


HLB, Xgate, Wonik IPS, Spear, LG Energy Solution



※ The above content is unrelated to the editorial direction of The Asia Business Daily. All responsibility lies with the information provider.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing